Hemato Oncology Testing Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segment

1.4.1. Market size breakdown, by offering

1.4.2. Market size breakdown, by cancer type

1.4.3. Market size breakdown, by technology

1.4.4. Market size breakdown, by end user

1.4.5. Market size breakdown, by region

1.4.6. Market size breakdown, by country

1.5. Market Data Reporting Unit

1.5.1. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

6.1. Market Dynamics

6.1.1. Trends

6.1.2. Drivers

6.1.3. Restraints/challenges

6.1.4. Impact analysis of drivers/restraints

6.2. Impact of COVID-19

6.3. Porter’s Five Forces Analysis

6.3.1. Bargaining power of buyers

6.3.2. Bargaining power of suppliers

6.3.3. Threat of new entrants

6.3.4. Intensity of rivalry

6.3.5. Threat of substitutes

Chapter 7. Global Market

7.1. Overview

7.2. Market Revenue, by Offering (2019–2030)

7.3. Market Revenue, by Cancer Type (2019–2030)

7.3.1. Leukemia testing market revenue, by type (2019–2030)

7.3.2. Lymphoma testing market revenue, by type (2019–2030)

7.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

7.4. Market Revenue, by Technology (2019–2030)

7.4.1. PCR market revenue, by type (2019–2030)

7.5. Market Revenue, by End User (2019–2030)

7.6. Market Revenue, by Region (2019–2030)

Chapter 8. North America Market

8.1. Overview

8.2. Market Revenue, by Offering (2019–2030)

8.3. Market Revenue, by Cancer Type (2019–2030)

8.3.1. Leukemia testing market revenue, by type (2019–2030)

8.3.2. Lymphoma testing market revenue, by type (2019–2030)

8.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

8.4. Market Revenue, by Technology (2019–2030)

8.4.1. PCR market revenue, by type (2019–2030)

8.5. Market Revenue, by End User (2019–2030)

8.6. Market Revenue, by Country (2019–2030)

Chapter 9. Europe Market

9.1. Overview

9.2. Market Revenue, by Offering (2019–2030)

9.3. Market Revenue, by Cancer Type (2019–2030)

9.3.1. Leukemia testing market revenue, by type (2019–2030)

9.3.2. Lymphoma testing market revenue, by type (2019–2030)

9.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

9.4. Market Revenue, by Technology (2019–2030)

9.4.1. PCR market revenue, by type (2019–2030)

9.5. Market Revenue, by End User (2019–2030)

9.6. Market Revenue, by Country (2019–2030)

Chapter 10. APAC Market

10.1. Overview

10.2. Market Revenue, by Offering (2019–2030)

10.3. Market Revenue, by Cancer Type (2019–2030)

10.3.1. Leukemia testing market revenue, by type (2019–2030)

10.3.2. Lymphoma testing market revenue, by type (2019–2030)

10.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

10.4. Market Revenue, by Technology (2019–2030)

10.4.1. PCR market revenue, by type (2019–2030)

10.5. Market Revenue, by End User (2019–2030)

10.6. Market Revenue, by Country (2019–2030)

Chapter 11. LATAM Market

11.1. Overview

11.2. Market Revenue, by Offering (2019–2030)

11.3. Market Revenue, by Cancer Type (2019–2030)

11.3.1. Leukemia testing market revenue, by type (2019–2030)

11.3.2. Lymphoma testing market revenue, by type (2019–2030)

11.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

11.4. Market Revenue, by Technology (2019–2030)

11.4.1. PCR market revenue, by type (2019–2030)

11.5. Market Revenue, by End User (2019–2030)

11.6. Market Revenue, by Country (2019–2030)

Chapter 12. MEA Market

12.1. Overview

12.2. Market Revenue, by Offering (2019–2030)

12.3. Market Revenue, by Cancer Type (2019–2030)

12.3.1. Leukemia testing market revenue, by type (2019–2030)

12.3.2. Lymphoma testing market revenue, by type (2019–2030)

12.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

12.4. Market Revenue, by Technology (2019–2030)

12.4.1. PCR market revenue, by type (2019–2030)

12.5. Market Revenue, by End User (2019–2030)

12.6. Market Revenue, by Country (2019–2030)

Chapter 13. U.S. Market

13.1. Overview

13.2. Market Revenue, by Offering (2019–2030)

13.3. Market Revenue, by Cancer Type (2019–2030)

13.3.1. Leukemia testing market revenue, by type (2019–2030)

13.3.2. Lymphoma testing market revenue, by type (2019–2030)

13.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

13.4. Market Revenue, by Technology (2019–2030)

13.4.1. PCR market revenue, by type (2019–2030)

13.5. Market Revenue, by End User (2019–2030)

Chapter 14. Canada Market

14.1. Overview

14.2. Market Revenue, by Offering (2019–2030)

14.3. Market Revenue, by Cancer Type (2019–2030)

14.3.1. Leukemia testing market revenue, by type (2019–2030)

14.3.2. Lymphoma testing market revenue, by type (2019–2030)

14.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

14.4. Market Revenue, by Technology (2019–2030)

14.4.1. PCR market revenue, by type (2019–2030)

14.5. Market Revenue, by End User (2019–2030)

Chapter 15. Germany Market

15.1. Overview

15.2. Market Revenue, by Offering (2019–2030)

15.3. Market Revenue, by Cancer Type (2019–2030)

15.3.1. Leukemia testing market revenue, by type (2019–2030)

15.3.2. Lymphoma testing market revenue, by type (2019–2030)

15.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

15.4. Market Revenue, by Technology (2019–2030)

15.4.1. PCR market revenue, by type (2019–2030)

15.5. Market Revenue, by End User (2019–2030)

Chapter 16. France Market

16.1. Overview

16.2. Market Revenue, by Offering (2019–2030)

16.3. Market Revenue, by Cancer Type (2019–2030)

16.3.1. Leukemia testing market revenue, by type (2019–2030)

16.3.2. Lymphoma testing market revenue, by type (2019–2030)

16.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

16.4. Market Revenue, by Technology (2019–2030)

16.4.1. PCR market revenue, by type (2019–2030)

16.5. Market Revenue, by End User (2019–2030)

Chapter 17. U.K. Market

17.1. Overview

17.2. Market Revenue, by Offering (2019–2030)

17.3. Market Revenue, by Cancer Type (2019–2030)

17.3.1. Leukemia testing market revenue, by type (2019–2030)

17.3.2. Lymphoma testing market revenue, by type (2019–2030)

17.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

17.4. Market Revenue, by Technology (2019–2030)

17.4.1. PCR market revenue, by type (2019–2030)

17.5. Market Revenue, by End User (2019–2030)

Chapter 18. Italy Market

18.1. Overview

18.2. Market Revenue, by Offering (2019–2030)

18.3. Market Revenue, by Cancer Type (2019–2030)

18.3.1. Leukemia testing market revenue, by type (2019–2030)

18.3.2. Lymphoma testing market revenue, by type (2019–2030)

18.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

18.4. Market Revenue, by Technology (2019–2030)

18.4.1. PCR market revenue, by type (2019–2030)

18.5. Market Revenue, by End User (2019–2030)

Chapter 19. Spain Market

19.1. Overview

19.2. Market Revenue, by Offering (2019–2030)

19.3. Market Revenue, by Cancer Type (2019–2030)

19.3.1. Leukemia testing market revenue, by type (2019–2030)

19.3.2. Lymphoma testing market revenue, by type (2019–2030)

19.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

19.4. Market Revenue, by Technology (2019–2030)

19.4.1. PCR market revenue, by type (2019–2030)

19.5. Market Revenue, by End User (2019–2030)

Chapter 20. Japan Market

20.1. Overview

20.2. Market Revenue, by Offering (2019–2030)

20.3. Market Revenue, by Cancer Type (2019–2030)

20.3.1. Leukemia testing market revenue, by type (2019–2030)

20.3.2. Lymphoma testing market revenue, by type (2019–2030)

20.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

20.4. Market Revenue, by Technology (2019–2030)

20.4.1. PCR market revenue, by type (2019–2030)

20.5. Market Revenue, by End User (2019–2030)

Chapter 21. China Market

21.1. Overview

21.2. Market Revenue, by Offering (2019–2030)

21.3. Market Revenue, by Cancer Type (2019–2030)

21.3.1. Leukemia testing market revenue, by type (2019–2030)

21.3.2. Lymphoma testing market revenue, by type (2019–2030)

21.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

21.4. Market Revenue, by Technology (2019–2030)

21.4.1. PCR market revenue, by type (2019–2030)

21.5. Market Revenue, by End User (2019–2030)

Chapter 22. India Market

22.1. Overview

22.2. Market Revenue, by Offering (2019–2030)

22.3. Market Revenue, by Cancer Type (2019–2030)

22.3.1. Leukemia testing market revenue, by type (2019–2030)

22.3.2. Lymphoma testing market revenue, by type (2019–2030)

22.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

22.4. Market Revenue, by Technology (2019–2030)

22.4.1. PCR market revenue, by type (2019–2030)

22.5. Market Revenue, by End User (2019–2030)

Chapter 23. Australia Market

23.1. Overview

23.2. Market Revenue, by Offering (2019–2030)

23.3. Market Revenue, by Cancer Type (2019–2030)

23.3.1. Leukemia testing market revenue, by type (2019–2030)

23.3.2. Lymphoma testing market revenue, by type (2019–2030)

23.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

23.4. Market Revenue, by Technology (2019–2030)

23.4.1. PCR market revenue, by type (2019–2030)

23.5. Market Revenue, by End User (2019–2030)

Chapter 24. South Korea Market

24.1. Overview

24.2. Market Revenue, by Offering (2019–2030)

24.3. Market Revenue, by Cancer Type (2019–2030)

24.3.1. Leukemia testing market revenue, by type (2019–2030)

24.3.2. Lymphoma testing market revenue, by type (2019–2030)

24.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

24.4. Market Revenue, by Technology (2019–2030)

24.4.1. PCR market revenue, by type (2019–2030)

24.5. Market Revenue, by End User (2019–2030)

Chapter 25. Brazil Market

25.1. Overview

25.2. Market Revenue, by Offering (2019–2030)

25.3. Market Revenue, by Cancer Type (2019–2030)

25.3.1. Leukemia testing market revenue, by type (2019–2030)

25.3.2. Lymphoma testing market revenue, by type (2019–2030)

25.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

25.4. Market Revenue, by Technology (2019–2030)

25.4.1. PCR market revenue, by type (2019–2030)

25.5. Market Revenue, by End User (2019–2030)

Chapter 26. Mexico Market

26.1. Overview

26.2. Market Revenue, by Offering (2019–2030)

26.3. Market Revenue, by Cancer Type (2019–2030)

26.3.1. Leukemia testing market revenue, by type (2019–2030)

26.3.2. Lymphoma testing market revenue, by type (2019–2030)

26.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

26.4. Market Revenue, by Technology (2019–2030)

26.4.1. PCR market revenue, by type (2019–2030)

26.5. Market Revenue, by End User (2019–2030)

Chapter 27. Saudi Arabia Market

27.1. Overview

27.2. Market Revenue, by Offering (2019–2030)

27.3. Market Revenue, by Cancer Type (2019–2030)

27.3.1. Leukemia testing market revenue, by type (2019–2030)

27.3.2. Lymphoma testing market revenue, by type (2019–2030)

27.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

27.4. Market Revenue, by Technology (2019–2030)

27.4.1. PCR market revenue, by type (2019–2030)

27.5. Market Revenue, by End User (2019–2030)

Chapter 28. South Africa Market

28.1. Overview

28.2. Market Revenue, by Offering (2019–2030)

28.3. Market Revenue, by Cancer Type (2019–2030)

28.3.1. Leukemia testing market revenue, by type (2019–2030)

28.3.2. Lymphoma testing market revenue, by type (2019–2030)

28.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

28.4. Market Revenue, by Technology (2019–2030)

28.4.1. PCR market revenue, by type (2019–2030)

28.5. Market Revenue, by End User (2019–2030)

Chapter 29. U.A.E. Market

29.1. Overview

29.2. Market Revenue, by Offering (2019–2030)

29.3. Market Revenue, by Cancer Type (2019–2030)

29.3.1. Leukemia testing market revenue, by type (2019–2030)

29.3.2. Lymphoma testing market revenue, by type (2019–2030)

29.3.3. Myeloproliferative neoplasms testing market revenue, by type (2019–2030)

29.4. Market Revenue, by Technology (2019–2030)

29.4.1. PCR market revenue, by type (2019–2030)

29.5. Market Revenue, by End User (2019–2030)

Chapter 30. Competitive Landscape

30.1. List of Market Players and Their Offerings

30.2. Competitive Benchmarking of Key Players

30.3. Product Benchmarking of Key Players

30.4. Recent Strategic Developments

Chapter 31. Company Profiles

31.1. Abbott Laboratories

31.1.1. Business overview

31.1.2. Product and service offerings

31.1.3. Key financial summary

31.2. F. Hoffmann-La Roche Ltd.

31.2.1. Business overview

31.2.2. Product and service offerings

31.2.3. Key financial summary

31.3. QIAGEN N.V.

31.3.1. Business overview

31.3.2. Product and service offerings

31.3.3. Key financial summary

31.4. Thermo Fisher Scientific Inc.

31.4.1. Business overview

31.4.2. Product and service offerings

31.4.3. Key financial summary

31.5. Bio-Rad Laboratories Inc.

31.5.1. Business overview

31.5.2. Product and service offerings

31.5.3. Key financial summary

31.6. Illumina Inc.

31.6.1. Business overview

31.6.2. Product and service offerings

31.6.3. Key financial summary

31.7. Invivoscribe Inc.

31.7.1. Business overview

31.7.2. Product and service offerings

31.8. ARUP Laboratories

31.8.1. Business overview

31.8.2. Product and service offerings

31.8.3. Key financial summary

31.9. ICON plc

31.9.1. Business overview

31.9.2. Product and service offerings

31.9.3. Key financial summary

31.10. Integrated DNA Technologies

31.10.1. Business overview

31.10.2. Product and service offerings

31.10.3. Key financial summary

31.11. Adaptive Biotechnologies Corporation

31.11.1. Business overview

31.11.2. Product and service offerings

31.11.3. Key financial summary

31.12. EntroGen Inc.

31.12.1. Business overview

31.12.2. Product and service offerings

Chapter 32. Appendix

32.1. Abbreviations

32.2. Sources and References

32.3. Related Reports

 

LIST OF TABLES

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 5 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 6 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 7 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 8 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 9 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 10 GLOBAL LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 11 GLOBAL LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 12 GLOBAL LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 13 GLOBAL LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 14 GLOBAL LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 15 GLOBAL LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 16 GLOBAL MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 17 GLOBAL MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 18 GLOBAL MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 19 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 20 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 21 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 22 GLOBAL PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 23 GLOBAL PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 24 GLOBAL PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 25 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 26 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 27 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 28 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY REGION, $M (2017–2022)

TABLE 29 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY REGION, $M (2023–2026)

TABLE 30 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY REGION, $M (2027–2030)

TABLE 31 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 32 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 33 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 34 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 35 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 36 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 37 NORTH AMERICA LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 38 NORTH AMERICA LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 39 NORTH AMERICA LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 40 NORTH AMERICA LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 41 NORTH AMERICA LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 42 NORTH AMERICA LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 43 NORTH AMERICA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 44 NORTH AMERICA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 45 NORTH AMERICA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 46 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 47 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 48 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 49 NORTH AMERICA PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 50 NORTH AMERICA PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 51 NORTH AMERICA PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 52 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 53 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 54 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 55 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 56 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 57 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 58 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 59 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 60 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 61 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 62 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 63 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 64 EUROPE LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 65 EUROPE LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 66 EUROPE LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 67 EUROPE LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 68 EUROPE LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 69 EUROPE LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 70 EUROPE MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 71 EUROPE MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 72 EUROPE MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 73 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 74 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 75 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 76 EUROPE PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 77 EUROPE PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 78 EUROPE PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 79 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 80 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 81 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 82 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 83 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 84 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 85 APAC HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 86 APAC HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 87 APAC HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 88 APAC HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 89 APAC HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 90 APAC HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 91 APAC LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 92 APAC LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 93 APAC LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 94 APAC LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 95 APAC LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 96 APAC LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 97 APAC MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 98 APAC MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 99 APAC MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 100 APAC HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 101 APAC HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 102 APAC HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 103 APAC PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 104 APAC PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 105 APAC PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 106 APAC HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 107 APAC HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 108 APAC HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 109 APAC HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 110 APAC HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 111 APAC HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 112 LATAM HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 113 LATAM HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 114 LATAM HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 115 LATAM HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 116 LATAM HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 117 LATAM HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 118 LATAM LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 119 LATAM LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 120 LATAM LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 121 LATAM LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 122 LATAM LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 123 LATAM LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 124 LATAM MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 125 LATAM MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 126 LATAM MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 127 LATAM HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 128 LATAM HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 129 LATAM HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 130 LATAM PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 131 LATAM PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 132 LATAM PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 133 LATAM HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 134 LATAM HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 135 LATAM HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 136 LATAM HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 137 LATAM HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 138 LATAM HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 139 MEA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 140 MEA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 141 MEA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 142 MEA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 143 MEA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 144 MEA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 145 MEA LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 146 MEA LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 147 MEA LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 148 MEA LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 149 MEA LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 150 MEA LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 151 MEA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 152 MEA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 153 MEA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 154 MEA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 155 MEA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 156 MEA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 157 MEA PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 158 MEA PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 159 MEA PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 160 MEA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 161 MEA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 162 MEA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 163 MEA HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 164 MEA HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 165 MEA HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 166 U.S. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 167 U.S. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 168 U.S. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 169 U.S. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 170 U.S. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 171 U.S. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 172 U.S. LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 173 U.S. LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 174 U.S. LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 175 U.S. LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 176 U.S. LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 177 U.S. LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 178 U.S. MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 179 U.S. MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 180 U.S. MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 181 U.S. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 182 U.S. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 183 U.S. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 184 U.S. PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 185 U.S. PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 186 U.S. PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 187 U.S. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 188 U.S. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 189 U.S. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 190 CANADA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 191 CANADA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 192 CANADA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 193 CANADA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 194 CANADA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 195 CANADA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 196 CANADA LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 197 CANADA LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 198 CANADA LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 199 CANADA LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 200 CANADA LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 201 CANADA LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 202 CANADA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 203 CANADA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 204 CANADA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 205 CANADA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 206 CANADA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 207 CANADA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 208 CANADA PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 209 CANADA PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 210 CANADA PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 211 CANADA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 212 CANADA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 213 CANADA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 214 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 215 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 216 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 217 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 218 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 219 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 220 GERMANY LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 221 GERMANY LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 222 GERMANY LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 223 GERMANY LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 224 GERMANY LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 225 GERMANY LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 226 GERMANY MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 227 GERMANY MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 228 GERMANY MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 229 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 230 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 231 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 232 GERMANY PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 233 GERMANY PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 234 GERMANY PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 235 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 236 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 237 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 238 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 239 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 240 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 241 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 242 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 243 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 244 FRANCE LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 245 FRANCE LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 246 FRANCE LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 247 FRANCE LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 248 FRANCE LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 249 FRANCE LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 250 FRANCE MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 251 FRANCE MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 252 FRANCE MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 253 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 254 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 255 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 256 FRANCE PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 257 FRANCE PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 258 FRANCE PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 259 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 260 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 261 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 262 U.K. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 263 U.K. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 264 U.K. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 265 U.K. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 266 U.K. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 267 U.K. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 268 U.K. LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 269 U.K. LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 270 U.K. LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 271 U.K. LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 272 U.K. LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 273 U.K. LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 274 U.K. MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 275 U.K. MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 276 U.K. MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 277 U.K. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 278 U.K. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 279 U.K. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 280 U.K. PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 281 U.K. PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 282 U.K. PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 283 U.K. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 284 U.K. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 285 U.K. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 286 ITALY HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 287 ITALY HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 288 ITALY HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 289 ITALY HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 290 ITALY HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 291 ITALY HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 292 ITALY LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 293 ITALY LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 294 ITALY LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 295 ITALY LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 296 ITALY LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 297 ITALY LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 298 ITALY MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 299 ITALY MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 300 ITALY MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 301 ITALY HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 302 ITALY HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 303 ITALY HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 304 ITALY PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 305 ITALY PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 306 ITALY PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 307 ITALY HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 308 ITALY HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 309 ITALY HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 310 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 311 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 312 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 313 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 314 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 315 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 316 SPAIN LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 317 SPAIN LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 318 SPAIN LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 319 SPAIN LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 320 SPAIN LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 321 SPAIN LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 322 SPAIN MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 323 SPAIN MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 324 SPAIN MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 325 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 326 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 327 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 328 SPAIN PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 329 SPAIN PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 330 SPAIN PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 331 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 332 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 333 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 334 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 335 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 336 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 337 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 338 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 339 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 340 JAPAN LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 341 JAPAN LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 342 JAPAN LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 343 JAPAN LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 344 JAPAN LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 345 JAPAN LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 346 JAPAN MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 347 JAPAN MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 348 JAPAN MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 349 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 350 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 351 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 352 JAPAN PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 353 JAPAN PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 354 JAPAN PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 355 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 356 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 357 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 358 CHINA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 359 CHINA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 360 CHINA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 361 CHINA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 362 CHINA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 363 CHINA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 364 CHINA LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 365 CHINA LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 366 CHINA LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 367 CHINA LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 368 CHINA LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 369 CHINA LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 370 CHINA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 371 CHINA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 372 CHINA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 373 CHINA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 374 CHINA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 375 CHINA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 376 CHINA PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 377 CHINA PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 378 CHINA PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 379 CHINA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 380 CHINA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 381 CHINA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 382 INDIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 383 INDIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 384 INDIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 385 INDIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 386 INDIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 387 INDIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 388 INDIA LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 389 INDIA LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 390 INDIA LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 391 INDIA LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 392 INDIA LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 393 INDIA LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 394 INDIA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 395 INDIA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 396 INDIA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 397 INDIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 398 INDIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 399 INDIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 400 INDIA PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 401 INDIA PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 402 INDIA PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 403 INDIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 404 INDIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 405 INDIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 406 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 407 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 408 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 409 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 410 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 411 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 412 AUSTRALIA LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 413 AUSTRALIA LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 414 AUSTRALIA LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 415 AUSTRALIA LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 416 AUSTRALIA LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 417 AUSTRALIA LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 418 AUSTRALIA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 419 AUSTRALIA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 420 AUSTRALIA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 421 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 422 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 423 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 424 AUSTRALIA PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 425 AUSTRALIA PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 426 AUSTRALIA PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 427 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 428 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 429 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 430 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 431 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 432 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 433 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 434 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 435 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 436 SOUTH KOREA LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 437 SOUTH KOREA LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 438 SOUTH KOREA LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 439 SOUTH KOREA LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 440 SOUTH KOREA LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 441 SOUTH KOREA LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 442 SOUTH KOREA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 443 SOUTH KOREA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 444 SOUTH KOREA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 445 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 446 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 447 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 448 SOUTH KOREA PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 449 SOUTH KOREA PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 450 SOUTH KOREA PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 451 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 452 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 453 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 454 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 455 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 456 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 457 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 458 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 459 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 460 BRAZIL LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 461 BRAZIL LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 462 BRAZIL LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 463 BRAZIL LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 464 BRAZIL LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 465 BRAZIL LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 466 BRAZIL MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 467 BRAZIL MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 468 BRAZIL MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 469 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 470 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 471 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 472 BRAZIL PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 473 BRAZIL PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 474 BRAZIL PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 475 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 476 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 477 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 478 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 479 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 480 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 481 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 482 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 483 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 484 MEXICO LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 485 MEXICO LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 486 MEXICO LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 487 MEXICO LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 488 MEXICO LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 489 MEXICO LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 490 MEXICO MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 491 MEXICO MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 492 MEXICO MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 493 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 494 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 495 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 496 MEXICO PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 497 MEXICO PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 498 MEXICO PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 499 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 500 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 501 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 502 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 503 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 504 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 505 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 506 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 507 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 508 SAUDI ARABIA LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 509 SAUDI ARABIA LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 510 SAUDI ARABIA LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 511 SAUDI ARABIA LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 512 SAUDI ARABIA LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 513 SAUDI ARABIA LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 514 SAUDI ARABIA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 515 SAUDI ARABIA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 516 SAUDI ARABIA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 517 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 518 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 519 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 520 SAUDI ARABIA PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 521 SAUDI ARABIA PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 522 SAUDI ARABIA PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 523 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 524 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 525 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 526 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 527 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 528 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 529 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 530 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 531 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 532 SOUTH AFRICA LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 533 SOUTH AFRICA LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 534 SOUTH AFRICA LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 535 SOUTH AFRICA LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 536 SOUTH AFRICA LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 537 SOUTH AFRICA LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 538 SOUTH AFRICA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 539 SOUTH AFRICA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 540 SOUTH AFRICA MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 541 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 542 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 543 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 544 SOUTH AFRICA PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 545 SOUTH AFRICA PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 546 SOUTH AFRICA PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 547 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 548 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 549 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 550 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2017–2022)

TABLE 551 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2023–2026)

TABLE 552 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2027–2030)

TABLE 553 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2017–2022)

TABLE 554 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2023–2026)

TABLE 555 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2027–2030)

TABLE 556 U.A.E. LEUKEMIA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 557 U.A.E. LEUKEMIA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 558 U.A.E. LEUKEMIA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 559 U.A.E. LYMPHOMA TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 560 U.A.E. LYMPHOMA TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 561 U.A.E. LYMPHOMA TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 562 U.A.E. MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 563 U.A.E. MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 564 U.A.E. MYELOPROLIFERATIVE NEOPLASMS TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 565 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 566 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 567 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 568 U.A.E. PCR MARKET, BY TYPE, $M (2017–2022)

TABLE 569 U.A.E. PCR MARKET, BY TYPE, $M (2023–2026)

TABLE 570 U.A.E. PCR MARKET, BY TYPE, $M (2027–2030)

TABLE 571 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 572 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 573 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 574 ABBOTT LABORATORIES – AT A GLANCE

TABLE 575 ABBOTT LABORATORIES – KEY FINANCIAL SUMMARY

TABLE 576 F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE

TABLE 577 F. HOFFMANN-LA ROCHE LTD. – KEY FINANCIAL SUMMARY

TABLE 578 QIAGEN N.V. – AT A GLANCE

TABLE 579 QIAGEN N.V. – KEY FINANCIAL SUMMARY

TABLE 580 THERMO FISHER SCIENTIFIC INC. – AT A GLANCE

TABLE 581 THERMO FISHER SCIENTIFIC INC. – KEY FINANCIAL SUMMARY

TABLE 582 BIO-RAD LABORATORIES INC. – AT A GLANCE

TABLE 583 BIO-RAD LABORATORIES INC. – KEY FINANCIAL SUMMARY

TABLE 584 ILLUMINA INC. – AT A GLANCE

TABLE 585 ILLUMINA INC. – KEY FINANCIAL SUMMARY

TABLE 586 INVIVOSCRIBE INC. – AT A GLANCE

TABLE 587 ARUP LABORATORIES – AT A GLANCE

TABLE 588 ARUP LABORATORIES – KEY FINANCIAL SUMMARY

TABLE 589 ICON PLC – AT A GLANCE

TABLE 590 ICON PLC – KEY FINANCIAL SUMMARY

TABLE 591 INTEGRATED DNA TECHNOLOGIES – AT A GLANCE

TABLE 592 INTEGRATED DNA TECHNOLOGIES – KEY FINANCIAL SUMMARY

TABLE 593 ADAPTIVE BIOTECHNOLOGIES CORPORATION – AT A GLANCE

TABLE 594 ADAPTIVE BIOTECHNOLOGIES CORPORATION – KEY FINANCIAL SUMMARY

TABLE 595 ENTROGEN INC. – AT A GLANCE

 

LIST OF FIGURES

FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 CURRENCY CONVERSION RATES FOR USD (2023)

FIG 8 GLOBAL HEMATO ONCOLOGY TESTING MARKET SUMMARY

FIG 9 BARGAINING POWER OF BUYERS

FIG 10 BARGAINING POWER OF SUPPLIERS

FIG 11 THREAT OF NEW ENTRANTS

FIG 12 INTENSITY OF RIVALRY

FIG 13 THREAT OF SUBSTITUTES

FIG 14 GLOBAL HEMATO ONCOLOGY TESTING MARKET SNAPSHOT

FIG 15 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 16 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 17 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 18 GLOBAL HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 19 MAJOR WORLDWIDE MARKETS FOR HEMATO ONCOLOGY TESTING SOLUTIONS, $M

FIG 20 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET SNAPSHOT

FIG 21 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 22 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 23 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 24 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 25 NORTH AMERICA HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 26 EUROPE HEMATO ONCOLOGY TESTING MARKET SNAPSHOT

FIG 27 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 28 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 29 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 30 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 31 EUROPE HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 32 APAC HEMATO ONCOLOGY TESTING MARKET SNAPSHOT

FIG 33 APAC HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 34 APAC HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 35 APAC HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 36 APAC HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 37 APAC HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 38 LATAM HEMATO ONCOLOGY TESTING MARKET SNAPSHOT

FIG 39 LATAM HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 40 LATAM HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 41 LATAM HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 42 LATAM HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 43 LATAM HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 44 MEA HEMATO ONCOLOGY TESTING MARKET SNAPSHOT

FIG 45 MEA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 46 MEA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 47 MEA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 48 MEA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 49 MEA HEMATO ONCOLOGY TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 50 U.S. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 51 U.S. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 52 U.S. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 53 U.S. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 54 CANADA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 55 CANADA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 56 CANADA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 57 CANADA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 58 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 59 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 60 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 61 GERMANY HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 62 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 63 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 64 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 65 FRANCE HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 66 U.K. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 67 U.K. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 68 U.K. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 69 U.K. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 70 ITALY HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 71 ITALY HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 72 ITALY HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 73 ITALY HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 74 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 75 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 76 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 77 SPAIN HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 78 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 79 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 80 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 81 JAPAN HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 82 CHINA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 83 CHINA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 84 CHINA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 85 CHINA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 86 INDIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 87 INDIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 88 INDIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 89 INDIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 90 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 91 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 92 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 93 AUSTRALIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 94 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 95 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 96 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 97 SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 98 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 99 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 100 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 101 BRAZIL HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 102 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 103 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 104 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 105 MEXICO HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 106 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 107 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 108 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 109 SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 110 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 111 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 112 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 113 SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 114 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY OFFERING, $M (2019–2030)

FIG 115 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY CANCER TYPE, $M (2019–2030)

FIG 116 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 117 U.A.E. HEMATO ONCOLOGY TESTING MARKET, BY END USER, $M (2019–2030)

FIG 118 ABBOTT LABORATORIES – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 119 F. HOFFMANN-LA ROCHE LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 120 QIAGEN N.V. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 121 THERMO FISHER SCIENTIFIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 122 BIO-RAD LABORATORIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 123 ILLUMINA INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 124 ARUP LABORATORIES – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 125 ICON PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 126 INTEGRATED DNA TECHNOLOGIES – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 127 ADAPTIVE BIOTECHNOLOGIES CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)